← Leaderboards
Meenalakshmi Chinnam
Roswell Park Cancer Institute Corp
$651,060
Attributed
$651,060
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $130.2K · FY2018–23$200K$150K$100K$50K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$651,060 · 1
By mechanism
R50$651,060 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Leigh Ellis$3,518,676
- Elizabeth Bouchard$7,979,280
- Xiang-Yang Wang$11,998,946
- Xuefang Cao$8,586,764
- Qiang Li$1,428,645
Others in their field
Other Emerging Leaders on “Novel Therapeutic Intervention”
- Leonard Freedman · Leidos Biomedical Research, Inc.$247,367,648
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Kathleen Maletic Neuzil · Emory University$26,258,144
Research focus
Novel Therapeutic InterventionAntiandrogen TherapyNeurosecretory SystemsBiochemistryCancer RelapseDoctor Of PhilosophyAnticancer ResearchNeoplasm MetastasisEpigenetic ProcessExhibitsFundingHistologyHistopathologyJournalsLaboratoriesMalignant Neoplasm Of ProstateAndrogen Deprivation TherapyAndrogen AntagonistsMolecularMolecular BiologyMolecular GeneticsMouse ModelMutationNutritional Science
Grant awards (5)
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation$130,212
R50 · FY2023 · CA · contact PI
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation$130,212
R50 · FY2022 · CA · contact PI
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation$130,212
R50 · FY2021 · CA · contact PI
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation$130,212
R50 · FY2020 · CA · contact PI
Evaluating candidate mediators of prostate cancer metastasis and neuro endocrine prostate cancer (NEPC) trans differentiation$130,212
R50 · FY2018 · CA · contact PI